Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

NEKTAR THERAPEUTICS (NKTR)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/23/2017 | 10:08am CET

NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 20, 2017, Nektar Therapeutics, a Delaware corporation (the “Company”), promoted Stephen K. Doberstein, Ph.D., who previously served as Senior Vice President and Chief Scientific Officer, to the position of Senior Vice President Research and Development and Chief Research and Development Officer. The full biography and other information of Dr. Doberstein required by Item 5.02(c) of Form 8-K are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2017 and the Company’s proxy statement on Schedule 14A for the 2017 annual meeting of stockholders filed with the SEC on May 1, 2017, and such biography and information are incorporated by reference into this Item 5.02.

In connection with the promotion, the compensation committee (the “Compensation Committee”) of the board of directors of the Company approved an increase of Dr. Doberstein’s 2017 annual base salary from $519,600 to $600,000 with an annual performance bonus target of at least 50% of his annual base salary. The actual amount of such performance bonus will range from 0% to 200% based on the Compensation Committee’s assessment of a combination of corporate and personal objectives.

On November 16, 2017, in connection with its focus on expanding development of its immuno-oncology pipeline, the Company decided to conclude its employment relationship with Ivan Gergel, M.D., who currently serves as the Senior Vice President, Drug Development and Chief Medical Officer. The Company recognizes Dr. Gergel for his contribution to the successful Phase 3 clinical trials for NKTR-181. The expected date of Dr. Gergel’s departure is December20, 2017 (the “Departure Date”). to the terms set forth in Dr. Gergel’s offer letter dated as of May 14, 2014 (the “Offer Letter”), Dr. Gergel and the Company agreed to enter into a separation and general release agreement in the event of a termination without cause. The Offer Letter was filed as Exhibit10.16 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the SEC on February 26, 2015. to the terms of the Offer Letter, Dr. Gergel is expected to enter into such separation and general release agreement.

About NEKTAR THERAPEUTICS (NASDAQ:NKTR)
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company’s drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

The post NEKTAR THERAPEUTICS (NASDAQ:NKTR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEKTAR THERAPEUTICS
10:08a NEKTAR THERAPEUTICS (NASDAQ : NKTR) Files An 8-K Departure of Directors or Certa..
11/22 NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
11/22 NEKTAR THERAPEUTICS : Announces Key Executive Promotions to Drive the Continued ..
11/21 First Data for NKTR-214 in Combination with OPDIVO® nivolumab for Patients wi..
11/16 NEKTAR THERAPEUTICS : NousCom's Neoantigen - based Vaccine Synergizes With NKTR-..
11/14 NEKTAR THERAPEUTICS : New Research Collaboration Between BioXcel Therapeutics an..
11/13 NEKTAR THERAPEUTICS : Bristol-Myers Gain on PIVOT Data Study
11/13 NEKTAR THERAPEUTICS : Other Events (form 8-K)
11/12 NEKTAR THERAPEUTICS : First Data for NKTR-214 in Combination with OPDIVO® (nivol..
11/10 NEKTAR THERAPEUTICS : to Webcast Presentation at Jefferies 2017 London Healthcar..
More news
News from SeekingAlpha
11/21 FDA issues guidance on development of generic abuse-deterrent opioids
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/16 Nektar Therapeutics (NKTR) Presents At Jefferies 2017 London Healthcare Confe..
11/15 YOUR DAILY PHARMA SCOOP : Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA A..
11/14 YOUR DAILY PHARMA SCOOP : Heron Undervalued, Theravance Submits NDA, Nektar Cont..
Financials ($)
Sales 2017 253 M
EBIT 2017 -78,5 M
Net income 2017 -124 M
Debt 2017 204 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 31,8x
EV / Sales 2018 36,1x
Capitalization 7 834 M
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 36,5 $
Spread / Average Target -27%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS307.34%7 834
CELLTRION, INC.--.--%24 331
IQVIA HOLDINGS INC37.23%21 966
INCYTE CORPORATION-1.32%20 893
LONZA GROUP62.21%19 860
ALNYLAM PHARMACEUTICALS, INC.252.59%13 012